Imperial Oil Limited Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Imperial Oil Limited Common Stock trades at $129.6 (market cap $62.22B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Imperial Oil Limited Common Stock is far larger — about 8.3× Spyre Therapeutics Inc. Common Stock's market cap, and Imperial Oil Limited Common Stock pays a 1.9% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| IMO | SYRE | |
|---|---|---|
Market Cap | $62.22B | $7.52B |
Volume | 560,544 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $138.33 | $108.92 |
52-Week Low | $83.72 | $22.18 |
Enterprise Value | $63.13B | $6.52B |
Dividend Yield | 1.9% | — |
Typical Hold Time | — | 0 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Imperial Oil Limited is a Canadian integrated energy company that explores for and produces crude oil and natural gas, operates oil sands projects at Cold Lake, Kearl, and Syncrude, and refines and markets petroleum products under the Esso and Mobil brands. ExxonMobil Corporation holds a majority ownership stake in the company.
Read more on IMO →Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →